Authors : Hala Hassan Deeb; Lojain Alsolaiman; Walid khaddam

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/47txmfu5

Scribd : https://tinyurl.com/5n6ezhmh

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY2436

Abstract : Background: One of the most prevalent endocrine disorders affecting women of reproductive age is Polycystic ovary syndrome (PCOS). The long-term health issues it can create in women, like obesity, diabetes, metabolic syndrome, and most significantly, infertility, are what make it so problematic.  Methods: Between July 2022 to the end of October 2022, Dr. Youssef Al-Hussein Center for Fertility and Infertility Treatment in Tartous conducted this study with two groups: patients (83) and healthy women (67). Blood samples were collected from patients and healthy subjects, and laboratory analyses were performed, including Anti-Mullerian Hormone (AMH) using Cobas e 411 devices, TSH analysis using an I chroma device, and AFC measuring using a transvaginal ultrasound probe.  Results: The levels of AMH and each factor (physical activity, smoking, TSH and BMI) did not significantly differ according to the statistical tests (P>0.05), but there was a clear statistical difference (P<0.05) in the relationship of AMH with age, showing that AMH decreased with advancing age. The association between AMH and AFC, where AMH was the quantitative expression of the antral follicle count (AFC), also showed a significant difference.  Conclusion: Smoking and physical activity had no impact on AMH levels, and neither did BMI or TSH levels. However, age clearly had an impact on AMH, and AMH was the quantitative representation of AFC.

Keywords : Polycystic Ovary Syndrome, Anti-Müllerian Hormone, Antral Follicle, Fertility.

References :

1. Afrin Yasmin, Shubhadeep Roychoudhury, Arun Paul Choudhury,et.al. Polycystic Ovary Syndrome: An Updated Overview Foregrounding Impacts of Ethnicities and Geographic Variations. Life (Basel)2022. Doi:10.3390/life12121974.
2. Sivanandy, M.S. Ha,S.K. The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome. Diagnostics 13, 907.2023.
3. Rumaisa Rashid, Suhail Ahmad Mir, et.al. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwanese Journal of Obstetrics and Gynecology. Vol 61, 2022, p 40-45.
4. Zhao, Y., Zhao, Y., Wang, C., Liang, Z. & Liu, X. Diagnostic Value of AntiMüllerian Hormone as a Biomarker for Polycystic Ovary Syndrome: A Meta-Analysis Update. Endocr. Pract. 25, 1056–1066 2019.
5. Suvarna Satish Khadilkar . Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?. Obstet Gyanecol India.  PMID: 27046960. 2016 Apr;66(2):81-7.
6. Mohd Zakwan Md Muslim, Aniza Mohammed Jelani, Noorazliyana Shafii, et.al. Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis. J Ovarian Res. 2024; 17: 106.
7. Teede, H., Deeks, A. & Moran, L. R Poly cystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. PMID: 20591140 .PMCID: PMC2909929 .2010.
8. Harada, M. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reprod. Med. Biol. 21. PMCID: PMC9601867.  2022.
9. Saxena, U., Ramani, M. & Singh, P. Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome. J. Obstet. Gynecol. India 68, 117–122 .2018.
10. Gassner, D. & Jung, R. First fully automated immunoassay for anti-Müllerian hormone. Clin. Chem. Lab. Med. CCLM 52, 2014.
11. Dewailly, D., Barbotin, A.-L., Dumont, A., Catteau-Jonard, S. & Robin, G. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome.Front. Endocrinol. 11, 641 .2020.
12. Moran, L. et al. Exercise Decreases Anti-Müllerian Hormone in Anovulatory Overweight Women with Polycystic Ovary Syndrome – A Pilot Study. Horm. Metab. Res. 43, 977–979 .2011.
13. Kazeminia, M., Rajati, F. & Rajati, M. The effect of exercise on anti-Mullerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Middle East Fertil. Soc. J. 27, 31. 2022.
14. Bhide, P. et al. Effect of cigarette smoking on serum anti-Mullerian hormone and antral follicle count in women seeking fertility treatment: a prospective crosssectional study. BMJ Open 12, e049646 2022.
15. Plante, B. J., Cooper, G. S., Baird, D. D. & Steiner, A. Z. The impact of smoking on antimüllerian hormone levels in women aged 38 to 50 years. Menopause 17, 571-576 .2010.
16. Dólleman M, Verschuren WMM, Eijkemans MJC, et al. Reproductive and lifestyle determinants of anti-Müllerian hormone in a large population-based study. J Clin Endocrinol Metab 98,2106–15 .2013.
17. Kabodmehri, R. et al. The relationship between thyroid function and ovarian reserve: a prospective cross-sectional study. Thyroid Res. 14, 22. 2021.
18. AL-Jaff, S. H. K. A negative correlation of thyroid stimulating hormone with anti_mullerian hormone and with luteinizing hormone in polycystic ovary syndrome and/or hypothyroid women. Middle East Fertil. Soc. J. 23, 388–392. (2018.
19. Park, H. T. et al. Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS): Insulin resistance and anti-Mullerian hormone. Clin. Endocrinol. (Oxf.) 72, 26–31. 2010.
20. Clinical Obesity - Kloos - The relationship between anti‐Mullerian hormone body mass index and weight loss A(2). 2022
21. Li, L. et al. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien. Klin. Wochenschr.122, 519-524. 2010.
22. Gougeon, A., Ecochard, R. & Thalabard, J. C. Age-Related Changes of the Population of Human Ovarian Follicles: Increase in the Disappearance Rate of NonGrowing and Early-Growing Follicles in Aging Women. Biol. Reprod. 50, 653–663 . 1994.
23. Laven, J. S. E. et al. Anti-Müllerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age. J. Clin. Endocrinol. Metab. 89, 318–323. 2004.